Niro joined Akoya in August 2020 to serve as the Chief Business Officer responsible for developing a robust roadmap and commercialization strategy for Akoya’s platforms. Niro has nearly two decades of experience in developing and commercializing products in the life science market. He has commercialized over 30 products across genomics and proteomics research markets. More recently, he served as the vice president of the spatial biology business unit at Nanostring Technologies (2014 – 2020). Prior to this, Niro led product development for the protein business unit at Life Technologies (2008-2014; acquired by Thermo Fisher). Niro received his Hon. BSc in Biochemistry from University of Toronto, and PhD from University of Windsor. He completed his post doctorate work at the Harvard Institute of Proteomics, Harvard University.
Clinical Dx showcase:
Our mission is to bring context to the world of biology and human health through the power of spatial phenotyping. Akoya’s single-cell imaging solutions phenotype cells with spatial context to visualize how they organize and interact to influence disease progression and treatment response
Scaling Up Single-Cell Spatial Biology Studies: From Basic Discovery
Speaking to the world of biology and human health through the power of spatial phenotyping.
Sequencing technologies are continuously improving, making it easier to obtain more in-depth molecular information than ever before. Emerging single-cell multi-omics sequencing technologies allow the capture of multiple modalities from a cell, including its epigenome, transcriptome, epitranscriptome, and proteome. This allows research into the heterogeneity of many biological mechanisms, and insights into complex molecular mechanisms that underpin disease.